World Breast Cancer Therapeutics Markets

SUMMARY

New Breast Cancer Therapies Focus on Improved Efficacy and Reduced Toxicity to Boost Uptake

The growing incidence of breast cancer among women worldwide highlights the huge commercial potential for breast cancer therapeutics. To serve this continual and increasing patient population, it is necessary to launch innovative products that overcome the significant side effects -- such as anemia and alopecia -- of prevailing treatments. The need is to develop a drug, which convinces the consumer of the competitive price, with increase survival time, low hospital costs, and easy reimbursement schemes. The main challenge is to reduce toxicity and improve efficacy in the new drug.

This Frost & Sullivan research service examines the global breast cancer therapeutics market. The study also provides insights into adjuvant products, cytotoxic, hormonal, and biologic sectors. It details industry challenges, and market drivers and restraints while giving an overview of the market revenues and shares.

New Indications for Adjuvant Products Drive Market Growth

Since breast cancer is a multifactor disease, no standardized medication is available to patients. This malignancy calls for a personalized treatment often used as an adjuvant setting or as a preventive measure. Besides mastectomy and radiotherapy, administration of therapeutics such as hormonal, cytotoxic, or biologic is used to improve the long-term outlook of the treatment.

"Efforts are being made across the industry to investigate the application of breast cancer therapies in an adjuvant setting and to obtain approval for using existing therapeutics of similar cancer indications to treat breast cancer," says the analyst of this study. Thus, the wider use of more combination therapies and early diagnosis system is likely to further spur market growth.

Successful Drug Development Ensures Sustained Growth of Breast Cancer Therapeutics Market

Market dynamics are set to change with generic companies entering the market. The most successful participants are the ones that collaborate with drug innovators to bring out new products. On the strength of these strategic partnerships the breast cancer therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.8 percent between 2004 and 2011.

The strongest growth is anticipated in the biologics sector, where only one product, Herceptin is currently available. "Expansion of Herceptin for new areas of breast cancer and as a preventative measure, as well as for the approval of other existing therapies for new breast cancer indications can further drive this sector," concludes the analyst.

TABLE OF CONTENTS

• 1. Executive Summary
  • 1. Executive Summary
    • 1. Executive Summary
• 2. Introduction
  • 1. Introduction to Breast Cancer
    • 1. Glossary
    • 2. Breast Cancer
  • 2. Therapeutic Targets for Breast Cancer
    • 1. Therapeutic Targets
    • 2. Genetic Targets
    • 3. Hormonal Targets
    • 4. Lifestyle Targets
• 3. Market Analysis
  • 1. Scope and Assumptions
    • 1. Research Service Scope
    • 2. Research Service Assumptions
  • 2. Breast Cancer Therapeutics
    • 1. Overview of Breast Cancer Therapeutics
    • 2. Cytotoxic Therapeutics
    • 3. Hormonal Therapeutics
    • 4. Biologic Therapeutics
  • 3. Market Challenges
    • 1. Industry Challenges for the World Breast Cancer Therapeutics Market
  • 4. Market Drivers and Restraints
    • 1. Market Drivers for the World Breast Cancer Therapeutics Market
      • a. Application of Existing Therapeutics for New Indications and Preventative Measures
      • b. Increasing Incidence of Breast Cancer
      • c. Drive towards Personalised Medicine Reveals a New Future for Cancer Therapy
      • d. Significant Funding and Publicity Facilitates Breast Cancer Research and Development
    • 2. Market Restraints for the World Breast Cancer Therapeutics Market
      • a. Spending Limits on Cancer Therapeutics
      • b. Lack of Consensus over Best Course of Treatment
      • c. Market Dominance of Major Participants deters Market Entrants
  • 5. World Market Analysis
    • 1. Market Analysis and Forecast
  • 6. United States Market Analysis
    • 1. Market Analysis and Forecast
  • 7. European Market Analysis
    • 1. Market Analysis and Forecast
• 4. Competitive Analysis
  • 1. Competitive Analysis
    • 1. Market Share Analysis
    • 2. Competitive Factors
  • 2. Company Profiles
    • 1. Industry Participants in the World Breast Cancer Therapeutics Market
• 5. Strategic Analysis and Recommendations
  • 1. Strategies for the World Breast Cancer Therapeutics Market
    • 1. Strategic Analysis
    • 2. Strategic Recommendations
• 6. Frost & Sullivan Awards
  • 1. Introduction to Frost & Sullivan Awards
    • 1. Industry Recognition
  • 2. Frost & Sullivan Awards
    • 1. Market Leadership Award
    • 2. Product Differentiation Innovation Award
• 7. Decision Support Databases
  • 1. Healthcare Market Metrics
    • 1. Healthcare Expenditure
    • 2. Government Healthcare Expenditure
    • 3. Private Healthcare Expenditure
  • 2. Cancer Incidence
    • 1. Incidence of Bladder Cancer
    • 2. Incidence of Breast Cancer
    • 3. Incidence of Colorectal Cancer
    • 4. Incidence of Liver Cancer
    • 5. Incidence of Lung Cancer
    • 6. Incidence of Prostate Cancer
    • 7. Incidence of Stomach Cancer